AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10665554
Drug: pyrimethamine-sulphadoxine plus
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight)
Trial: 10665554
Drug: pyrimethamine-sulphadoxine plus
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrimethamine-sulphadoxine plus three doses of artesunate (4 mg/kg bodyweight daily for 3 days)
Trial: 9091006
Drug: Oestrogel (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogel (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Trial: 9091006
Drug: Estreva (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estreva (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Trial: 8374375
Drug: Glibenclamide regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide regimen 1: usual morning dose in the evening and evening dose before dawn
Trial: 8374375
Drug: Glibenclamide regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide regimen 2: usual morning dose in the evening and evening dose before dawn with a reduction of total dose by a quarter
Trial: 31786086
Drug: Additional ultrasound-accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional ultrasound-accelerated catheter-directed thrombolysis (urokinase with a starting bolus of 250,000 IU in 10 mL NaCl followed by 100,000 IU/h for a maximum of 96 h)
Trial: 31786086
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (anticoagulant therapy, compression therapy, early ambulation)
Trial: 28591675
Drug: Ramucirumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (8 mg/kg)
Trial: 23876463
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (IGC) for almost 24 h after PCI (n = 54; target glucose 80-140 mg/dl)
Trial: 23876463
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic control (CGC) (n = 52; target glucose 180-200 mg/dl)
Trial: 21654268
Drug: Febuxostat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (all doses)
Trial: 19261960
Drug: Subcutaneous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tramadol infiltration
Trial: 19261960
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol administration
Trial: 15310527
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin daily for 24 weeks
Trial: 9412311
Drug: Vitamin B6,
RxNorm normalized name: Vitamin B6, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B6, 50 mg/d
Trial: 9412311
Drug: Folic acid,
RxNorm normalized name: folic acid, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d
Trial: 9412311
Drug: Vitamin B6,
RxNorm normalized name: Vitamin B6, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B6, 50 mg/d, folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d
Trial: 3146370
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (100 mg over three hours)
Trial: 30221006
Drug: Immediate-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release metformin 250 mg
Trial: 30221006
Drug: Immediate-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release metformin 500 mg
Trial: 30221006
Drug: Immediate-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release metformin 1000 mg
Trial: 27406936
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (Gardasil)
Trial: 19564902
Drug: Pralidoxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pralidoxime (2 g loading dose over 20 min, followed by 0.5 g/h for up to 7 days)
Trial: 16724996
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (900 mg)
Trial: 16724996
Drug: High-dose ulinastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ulinastatin (450,000 units)
Trial: 16724996
Drug: Low-dose ulinastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ulinastatin (150,000 units)
Trial: 14655042
Drug: Treatment outcomes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment outcomes
Trial: 8487666
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (200 mg/wk intramuscularly)
Trial: 8487666
Drug: Testolactone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testolactone (250 mg four times per day)
Trial: 3232537
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (2 different doses)
Trial: 3232537
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (test drug and placebo)
Trial: 29298660
Drug: Fractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated stereotactic radiotherapy to the resection cavity (total dose of 46 Gy in 2 Gy per fraction or 36 Gy in 3 Gy per fraction)
Trial: 24569129
Drug: QVA149 (440/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 (440/200 μg)
Trial: 23699763
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (0.5 μg/kg/min for 4 hours)
Trial: 18427133
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 to 10 mg) for 8 weeks
Trial: 16048650
Drug: trimethoprim/sulfamethoxazole 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim/sulfamethoxazole 1 double-strength tablet twice daily for 3 days
Trial: 16048650
Drug: ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 250 mg twice daily for 3 days
Trial: 16048650
Drug: nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrofurantoin 100 mg twice daily for 7 days
Trial: 7541860
Drug: 560 mg
RxNorm normalized name: spinosad 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 mg estramustine phosphate daily for 6 weeks preoperatively
Trial: 849020
Drug: Metrifonate (Bilarcil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (Bilarcil Bayer AG) at a dose rate of 7.5 mg/kg once per fortnight for three doses during therapy stage and four-weekly during prophylaxis stage.
Trial: 12712083
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution placebo
Trial: 13679971
Drug: Grouped dosage
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grouped dosage of immunotherapy
Trial: 13679971
Drug: Conventional dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosage of immunotherapy
Trial: 2065403
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation every day for three months (G1)
Trial: 2065403
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation for anaemic infants (G3)
Trial: 31036058
Drug: Integrative improvisational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative improvisational music therapy (IIMT) alone
Trial: 31036058
Drug: Integrative improvisational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative improvisational music therapy (IIMT) with home‐based listening (LH)
Trial: 31036058
Drug: Integrative improvisational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative improvisational music therapy (IIMT) with resonance frequency breathing (RFB)
Trial: 31036058
Drug: Integrative improvisational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative improvisational music therapy (IIMT) with both enhancements (LH and RFB)
Trial: 22732975
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum CECT 7315/7316 (5*10^9 cfu/day) in 20 g powdered skim milk
Trial: 22732975
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum CECT 7315/7316 (5*10^8 cfu/day) in 20 g powdered skim milk
Trial: 22732975
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 g powdered skim milk)
Trial: 24491070
Drug: Assessment-only (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment-only (treatment as usual)
Trial: 19650856
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of erythropoietic stimulating agents and/or intravenous iron
Trial: 16814449
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous combined therapy (Group A, n = 31)
Trial: 16814449
Drug: Transdermal sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal sequential hormone replacement therapy (Group B, n = 30)
Trial: 12003685
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment with antidepressants for patients with COPD and depression
Trial: 10092716
Drug: Lidocaine iontophoresis
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine iontophoresis (1 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 10092716
Drug: Control (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1 mL of 0.9% saline solution with 1:100,000 epinephrine)
Trial: 2256875
Drug: Phenytoin (anticonvulsant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (anticonvulsant dose)
Trial: 7362955
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of cotrimoxazole and metronidazole
Trial: 7362955
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of cotrimoxazole and metronidazole for 5 days
Trial: 7362955
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose group
Trial: 7362955
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses group
Trial: 31512832
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after tooth extraction (Control group)
Trial: 11716207
Drug: Formoterol (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (9 microg per inhalation, total cumulative dose of 27 microg)
Trial: 3297895
Drug: Diethylamine persilate
RxNorm normalized name: diethylamine salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylamine persilate (DAP) 1.5 g/day
Trial: 3297895
Drug: Diethylamine persilate
RxNorm normalized name: diethylamine salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylamine persilate (DAP) 2.5 g/day
Trial: 3297895
Drug: Diethylamine persilate
RxNorm normalized name: diethylamine salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylamine persilate (DAP) 0.5 g/day
Trial: 27565118
Drug: Improved Treatment
RxNorm normalized name: Hybolin-Improved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved Treatment as Usual (iTAU)
Trial: 22962030
Drug: Sequential add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential add-on treatment
Trial: 23117107
Drug: Iyengar yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iyengar yoga program (9-week, weekly 90-minute classes)
Trial: 15086924
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement taken with meal (1 g of calcium carbonate, 3 times/day)
Trial: 15086924
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement taken at bedtime (3 g/day of calcium carbonate)
Trial: 7502689
Drug: Ethinylestradiol 20
RxNorm normalized name: Ethinylestradiol 20 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 20 micrograms/day + calcium 500 mg/day
Trial: 2091186
Drug: Electrolyte‐polyethylene glycol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte‐polyethylene glycol solution (SE‐PEG)
Trial: 2091186
Drug: Standard bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bowel preparation (SBP)
Trial: 28237552
Drug: Traditional speech
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional speech therapy
Trial: 15096071
Drug: Venlafaxine, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine, 100 to 200 mg/day for 12 months
Trial: 11774146
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine solution via an infusion pump (2 mL each hour for 48 hours)
Trial: 11774146
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution via an infusion pump (2 mL each hour for 48 hours)
Trial: 11477812
Drug: Buyang Huanwu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buyang Huanwu Decoction (BHD) in Chinese medicine group (CMG)
Trial: 11477812
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch injection and enteric coated aspirin tablets in western medicine group (WMG)
Trial: 7650234
Drug: Lidocaine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (200 mg) plus adrenalin (1:200,000)
Trial: 26892922
Drug: Modafinil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (400 mg/day for 26 days, then 300 mg/day for 30 days, and 200 mg/day for 31 days)
Trial: 21073082
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Gentamycin 80 mg IV (immediately after spinal anesthesia)
Trial: 21073082
Drug: Extended use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended use of Amoxicillin, Chloramphenicol or Cotrimexazole (postoperatively)
Trial: 21073082
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Gentamycin 80 mg IV
Trial: 21073082
Drug: Extended use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended use of Amoxicillin, Chloramphenicol or Cotrimexazole
Trial: 17981377
Drug: Purified duck
RxNorm normalized name: Duck
DrugBank: Duck (DB10610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified duck embryo vaccine (PDEV, Vaxirab)
Trial: 17981377
Drug: Purified duck
RxNorm normalized name: Duck
DrugBank: Duck (DB10610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified duck embryo vaccine (Lyssavac)
Trial: 7859239
Drug: Sustained-release Uni-Dur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Uni-Dur 600-mg theophylline tablet to fasting subjects
Trial: 7859239
Drug: Sustained-release Uni-Dur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Uni-Dur 600-mg tablet after a high-fat meal
Trial: 7859239
Drug: Sustained-release Uni-Dur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Uni-Dur 600-mg dose administered as two half tablets to fasting subjects
Trial: 7859239
Drug: Sustained-release Uni-Dur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Uni-Dur 400-mg tablet to fasting subjects
Trial: 7859239
Drug: Immediate-release theophylline
RxNorm normalized name: theophylline Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release theophylline (Slo-Phyllin) 5 x 100 mg to fasting subjects
Trial: 7859239
Drug: Sustained-release Uni-Dur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Uni-Dur 600-mg fasting treatment
Trial: 7859239
Drug: Sustained-release Uni-Dur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release Uni-Dur 400-mg treatment
Trial: 2570730
Drug: famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine (40 mg at bedtime)
Trial: 28222072
Drug: Central re-testing
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central re-testing of receptor status
Trial: 26130251
Drug: S-Adenosylmethionine (SAMe)
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Adenosylmethionine (SAMe) 2.4 g/d for 24 weeks
Trial: 24277402
Drug: Enteral plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral plus parenteral nutrition (EN+PN)
Trial: 21615968
Drug: GP management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP management with adjunctive counselling (CBT)
Trial: 21615968
Drug: GP management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP management with adjunctive counselling (CBT) delivered by postnatal nurses or psychologists
Trial: 12752349
Drug: PAC (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC (pantoprazole 40 mg, clarithromycin 500 mg, amoxicillin 1000 mg)
Trial: 12752349
Drug: PAM (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAM (pantoprazole 40 mg, amoxicillin 1000 mg, metronidazole 500 mg)
Trial: 8820890
Drug: 22.2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.2 g dibasic calcium phosphate (DCP)
Trial: 3495089
Drug: Induction 2
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction 2 mg kg‐1, infusion rate 9 mg kg‐1 h‐1 (Group 1)
Trial: 3495089
Drug: Induction 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction 2.5 mg kg‐1, infusion rate 12 mg kg‐1 h‐1 (Group 2)
Trial: 3495089
Drug: Induction 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction 2.5 mg kg‐1, infusion rate 9 mg kg‐1 (Group 3)
Trial: 25496482
Drug: Avoidance plan
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Avoidance plan (radiotherapy optimized to minimize dose to functional lung)
Trial: 18354721
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic and steroid lumbar facet joint nerve blocks
Trial: 10494113
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training (both pelvic floor muscle training and bladder training)
Trial: 368354
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride 200 mg daily
Trial: 22008819
Drug: HRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRV vaccine (Rotarix™)
Trial: 11385189
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (TET)
Trial: 9092956
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at target dosages of 200-1,000 mg daily
Trial: 1623901
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 6-mercaptopurine (30 mg/m2)
Trial: 1623901
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 6-mercaptopurine (87.5 mg/m2)
Trial: 1623901
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 6-mercaptopurine
Trial: 30864472
Drug: Sequential IPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential IPC for 10 minutes
Trial: 30864472
Drug: Sequential IPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential IPC compared to Single-compartment IPC
Trial: 15172083
Drug: Exercise three‐times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise three‐times weekly over 12 weeks